Company News: BellaSeno’s Senella® Medical Implant Technology Named a Bronze Winner of the 2020 Edison Awards
BellaSeno GmbH, an ISO 13485-certified medtech company developing absorbable scaffolds using additive manufacturing technologies, today announced that its Senella® implant technology has won a Bronze Edison Award 2020 in the category Medical / Dental, subcategory Medical Implants.
Senella® is a patented porous scaffold made of absorbable Polycaprolactone (PCL) containing highly-specialized topological and design features, which act as recipients for injected fat tissue isolated with a standard liposuction procedure. The implant is designed to get absorbed over a span of two years and to provide a stable platform for the injected fat tissue to mature, adapt to its environment and stabilize. The clinical end result is a natural breast tissue – without remnants of foreign material. Senella® therefore has the potential to alleviate the complications found in current breast reconstruction and augmentation approaches.
Among the nomination entries comprising the best products, services, and businesses in innovation for the year 2020, Senella® was chosen as a winner by a panel of over 3,000 leading business executives from around the world.
“After a thorough review, the Edison Awards Judges recognize Senella as a game-changing innovation standing out among the best new products and services launched in their category,” said Frank Bonafilia, Executive Director of the Edison Awards.
“Senella is a result of more than ten years of research and development efforts,” said Dr. Mohit P. Chhaya, co-founder and Chief Technology Officer of BellaSeno. “I would like to thank the entire BellaSeno team for their untiring efforts and their collaborative spirit that made this success possible.”
“We are proud to have received a Bronze Edison Award for our proprietary Senella technology,” said Sara Lucarotti, Head of Design of BellaSeno. “Our novel breast implants are designed to significantly limit the risk of potential side-effects common in breast reconstruction. Ultimately, our goal is to provide breast reconstruction patients with fully natural breasts and a high quality of life after surgery.”